AndreaBozzo/ceres-open-data-index huggingface dataset:
Longitudinal Studies on Child Abuse and Neglect (LONGSCAN) ages 0-18

LONGSCAN is a consortium of research studies operating under common by-laws and procedures.  It was initiated in 1991 with grants from the National Center on Child Abuse and Neglect to a coordinating center at the University of North Carolina at Chapel Hill and five data collection sites.  Each site is conducting a separate and unique research project on the etiology and impact of child maltreatment.  While each project can stand on its own merits, through the use of common assessment measures, similar data collection methods and schedules, and pooled analyses, LONGSCAN is a collaborative effort that is truly greater than the sum of its parts.
     The goal of LONGSCAN is to follow the 1300+ children and their families until the children themselves become young adults.    Maltreatment data are collected from multiple sources, including review of Child Protective Service records every two years.  Yearly telephone interviews allow the sites to track families and assess yearly service utilization and important life events.
       In addition to the specific focus of the individual studies, the coordinated LONGSCAN design permits a comprehensive exploration of many critical issues in child abuse and neglect on a combined sample of sufficient size for unprecedented statistical power and flexibility.  Built into the LONGSCAN design is also the ability to replicate and extend findings across a variety of ethnic, social and economic subgroups.
    The findings of LONGSCAN will provide a scientific basis for policy-making, program planning, and targeting service delivery by increasing our understanding of the following:

Investigators: Runyan, D., Dubowitz, H., English, D., Kotch, J., Litrownik, A., & Thompson, R.
NNDSS - TABLE 1N. Haemophilus influenzae, invasive disease, Age <5 years, Non-b serotype to Unknown serotype

NNDSS - TABLE 1N. Haemophilus influenzae, invasive disease, Age <5 years, Non-b serotype to Unknown serotype - 2022. In this Table, provisional cases* of notifiable diseases are displayed for United States, U.S. territories, and Non-U.S. residents.

Notes:

•	These are weekly cases of selected infectious national notifiable diseases, from the National Notifiable Diseases Surveillance System (NNDSS). NNDSS data reported by the 50 states, New York City, the District of Columbia, and the U.S. territories are collated and published weekly as numbered tables available at https://www.cdc.gov/nndss/data-statistics/index.html. Cases reported by state health departments to CDC for weekly publication are subject to ongoing revision of information and delayed reporting. Therefore, numbers listed in later weeks may reflect changes made to these counts as additional information becomes available. Case counts in the tables are presented as published each week. See also Guide to Interpreting Provisional and Finalized NNDSS Data at https://www.cdc.gov/nndss/docs/Readers-Guide-WONDER-Tables-20210421-508.pdf.
• Notices, errata, and other notes are available in the Notice To Data Users page at https://wonder.cdc.gov/nndss/NTR.html.
•	The list of national notifiable infectious diseases and conditions and their national surveillance case definitions are available at https://ndc.services.cdc.gov/. This list incorporates the Council of State and Territorial Epidemiologists (CSTE) position statements approved by CSTE for national surveillance.

Footnotes:

*Case counts for reporting years 2021 and 2022 are provisional and subject to change. Cases are assigned to the reporting jurisdiction submitting the case to NNDSS, if the case's country of usual residence is the U.S., a U.S. territory, unknown, or null (i.e. country not reported); otherwise, the case is assigned to the 'Non-U.S. Residents' category. Country of usual residence is currently not reported by all jurisdictions or for all conditions. For further information on interpretation of these data, see https://www.cdc.gov/nndss/docs/Readers-Guide-WONDER-Tables-20210421-508.pdf.
†Previous 52 week maximum and cumulative YTD are determined from periods of time when the condition was reportable in the jurisdiction (i.e., may be less than 52 weeks of data or incomplete YTD data).
U: Unavailable — The reporting jurisdiction was unable to send the data to CDC or CDC was unable to process the data.
-: No reported cases — The reporting jurisdiction did not submit any cases to CDC.
N: Not reportable — The disease or condition was not reportable by law, statute, or regulation in the reporting jurisdiction.
NN: Not nationally notifiable — This condition was not designated as being nationally notifiable.
NP: Nationally notifiable but not published.
NC: Not calculated — There is insufficient data available to support the calculation of this statistic.
Cum: Cumulative year-to-date counts.
Max: Maximum — Maximum case count during the previous 52 weeks.
14th National Conference on Child Abuse and Neglect Presentation Materials

This page contains a collection of presentations and handouts from meetings, plenary and poster sessions, preconference and skills seminars, think tanks, and workshops held at the conference.

CAPTA Research Grantees’ Annual Meeting – OCAN's Grantees' Meeting Opening Session (PDF) (PDF - 60 KB), presented by Sally Flanzer, Ph.D.

The Relation of Adult Health to Adverse Childhood Experiences – Opening Plenary Keynote (PDF) (PDF - 515 KB), presented by Vincent Felitti, M.D., and Robert F. Anda, M.D.
Attachments Past and Present: Implications for the Prevention of Child Maltreatment – Plenary One Keynote (PDF) (PDF - 424 KB), presented by Byron Egeland, Ph.D.

Great Beginnings Start Before Birth: Strengthening Families through Early Prenatal Support Services and Father Involvement – Session 1 (PDF) (PDF - 40 KB), presented by Helen Reif
CAPTA Amendments 2003: How Changes in Federal Law Can Affect State Agency Programs – Session 2 (PDF) (PDF - 64 KB), Presented by Suzan Cohen

Management of Ethical Issues and Conflicts of Interest – Seminar B (PDF) (PDF - 51 KB), presented by Pamela R. Montgomery, A.C.S.W., and Elizabeth D. Still, M.A.

Child and Animal Welfare: The Roots of Collaborative Programs and Re-Emergence of Interagency and Interdisciplinary Efforts – Skills Seminar C (PDF) (PDF - 45 KB), presented by Frank R. Ascione, Ph.D., and Deborah Ascione
“The Relational Worldview:” A Tribal and Cultural Framework for Service Delivery and Program Development – Skills Seminar D (PDF) (PDF - 269 KB) Handout  (PDF)(PDF - 35 KB), presented by Andy Hunt, M.S.W., and Nadja Printup, M.S.W.
Effective Parent Leadership: A Practical Approach to Meaningful Partnerships Between Parents and Providers – Skills Seminar F (PDF) (PDF - 62 KB), presented by Teresa Rafael, M.S.W., Margaret Polinsky, Ph.D., Tanya Long, and Bunti Reed
Abuse and Neglect of Children with Disabilities: A Collaborative Response – Skills Seminar I (PDF) (PDF - 88 KB), presented by Peggy O’Neill, Brian Colligan, and Vernon Simmons
Quality Assurance, Risk Management and Documentation in the Record – Skills Seminar K (PDF) (PDF - 48 KB), presented by Bob Mitchell, A.C.S.W.
Parent Child Interaction Therapy: Training for Professionals Working with High-Risk Families – Skills Seminar M (PDF) (PDF - 3,064 KB) Handout  (PDF)(PDF - 82 KB), presented by Georganna Sedlar, Ph.D., Katherine Elliott, Ph.D., and Anthony Urquiza, Ph.D.

Formulating a Multidisciplinary Comprehensive Research Agenda for the Prevention of Child Maltreatment (PDF) (PDF - 99 KB), presented by John Holton, Kathryn Harding, Nancy Peddle
Tough Problems, Tough Choices: Casey's Guidelines for Needs-Based Service Planning in Child Welfare (PDF) (PDF - 235 KB), presented by Amy Printz Wintefeld, J.D., and Tracey Feild

Metadata-only record linking to the original dataset. Open original dataset below.
The Paired Availability Design for Historical Controls

Background
          Although a randomized trial represents the most rigorous method of evaluating a medical intervention, some interventions would be extremely difficult to evaluate using this study design. One alternative, an observational cohort study, can give biased results if it is not possible to adjust for all relevant risk factors.
        
        
          Methods
          A recently developed and less well-known alternative is the paired availability design for historical controls. The paired availability design requires at least 10 hospitals or medical centers in which there is a change in the availability of the medical intervention. The statistical analysis involves a weighted average of a simple "before" versus "after" comparison from each hospital or medical center that adjusts for the change in availability.
        
        
          Results
          We expanded requirements for the paired availability design to yield valid inference. (1) The hospitals or medical centers serve a stable population. (2) Other aspects of patient management remain constant over time. (3) Criteria for outcome evaluation are constant over time. (4) Patient preferences for the medical intervention are constant over time. (5) For hospitals where the intervention was available in the "before" group, a change in availability in the "after group" does not change the effect of the intervention on outcome.
        
        
          Conclusion
          The paired availability design has promise for evaluating medical versus surgical interventions, in which it is difficult to recruit patients to a randomized trial.
Identifying older diabetic patients at risk of poor glycemic control

Background
          Optimal glycemic control prevents the onset of diabetes complications. Identifying diabetic patients at risk of poor glycemic control could help promoting dedicated interventions. The purpose of this study was to identify predictors of poor short-term and long-term glycemic control in older diabetic in-patients.
        
        
          Methods
          A total of 1354 older diabetic in-patients consecutively enrolled in a multicenter study formed the training population (retrospective arm); 264 patients consecutively admitted to a ward of general medicine formed the testing population (prospective arm). Glycated hemoglobin (HbA1c) was measured on admission and one year after the discharge in the testing population. Independent correlates of a discharge glycemia ≥ 140 mg/dl in the training population were assessed by logistic regression analysis and a clinical prediction rule was developed. The ability of the prediction rule and that of admission HbA1c to predict discharge glycemia ≥ 140 mg/dl and HbA1c > 7% one year after discharge was assessed in the testing population.
        
        
          Results
          Selected admission variables (diastolic arterial pressure < 80 mmHg, glycemia = 143–218 mg/dl, glycemia > 218 mg/dl, history of insulinic or combined hypoglycemic therapy, Charlson's index > 2) were combined to obtain a score predicting a discharge fasting glycemia ≥ 140 mg/dl in the training population. A modified score was obtained by adding 1 if admission HbA1c exceeded 7.8%. The modified score was the best predictor of both discharge glycemia ≥ 140 mg/dl (sensitivity = 79%, specificity = 63%) and 1 year HbA1c > 7% (sensitivity = 72%, specificity = 71%) in the testing population.
        
        
          Conclusion
          A simple clinical prediction rule might help identify older diabetic in-patients at risk of both short and long term poor glycemic control.
Survival of patients transferred to tertiary intensive care from rural community hospitals

Background:
          Accessibility to tertiary intensive care resources differs among hospitals within a rural region. Determining whether accessibility is associated with outcome is important for understanding the role of regionalization when providing critical care to a rural population.
        
        
          Methods:
          In a prospective design, we identified and recorded the mortality ratio, percentage of unanticipated deaths, length of stay in the intensive care unit (ICU), and survival time of 147 patients transferred directly from other hospitals and 178 transferred from the wards within a rural tertiary-care hospital.
        
        
          Results:
          The two groups did not differ significantly in the characteristics measured. Differences in access to tertiary critical care in this rural region did not affect survival or length of stay after admission to this tertiary ICU. The odds ratio (1.14; 95% confidence interval 0.72-1.83) for mortality associated with transfer from a rural community hospital was not statistically significant.
        
        
          Conclusions:
          Patients at community hospitals in this area who develop need for tertiary critical care are just as likely to survive as patients who develop ICU needs on the wards of this rural tertiary-care hospital, despite different accessibility to tertiary intensive-care services.
Compound 530195: 1H-Indole-3-acetic acid, 1-(trimethylsilyl)-, trimethylsilyl ester

Chemical compound data from PubChem database. IUPAC Name: trimethylsilyl 2-(1-trimethylsilylindol-3-yl)acetate. Molecular Formula: C16H25NO2Si2. Molecular Weight: 319.54. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 525577: N,N-Dimethyl-N'-(3-methylphenyl)-benzamidine

Chemical compound data from PubChem database. IUPAC Name: N,N-dimethyl-N'-(3-methylphenyl)benzenecarboximidamide. Molecular Formula: C16H18N2. Molecular Weight: 238.33. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Metabolomics Workbench (MetWB)

<p>The Metabolomics Program's Data Repository and Coordinating Center (DRCC), housed at the San Diego Supercomputer Center (SDSC), University of California, San Diego, has developed the Metabolomics Workbench. MetWB will serve as a national and international repository for metabolomics data and metadata and will provide analysis tools and access to metabolite standards, protocols, tutorials, training, and more.</p>
Compound 530202: 2-[(Trimethylsilyl)oxy]-3-[1-(trimethylsilyl)-1H-indol-3-YL]propenoic acid trimethylsilyl ester

Chemical compound data from PubChem database. IUPAC Name: trimethylsilyl 3-(1-trimethylsilylindol-3-yl)-2-trimethylsilyloxyprop-2-enoate. Molecular Formula: C20H33NO3Si3. Molecular Weight: 419.7. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Cloning and characterization of the rat homologues of the Inhibitor of Apoptosis protein 1, 2, and 3 genes.

Background
          Inhibitor of Apoptosis (IAP) proteins are key intrinsic regulators of apoptosis induced by a variety of triggers. We isolated the rat Inhibitor of Apoptosis genes 1, 2 and 3 and characterized their tissue distribution and expression.
        
        
          Results
          Rat iap-1 encodes a protein of 67.1 kDa with 73 % and 89.2 % homology to human and mouse iap-1 respectively. Rat iap-2 encodes a protein of 66.7 kDa with 81.6 % and 89.3 % homology to human and mouse iap-2 respectively. Rat iap-3 encodes a protein of 56.1 kDa with 89.5 % and 93.1 % homology to human and mouse iap-3 respectively. We have generated rabbit polyclonal antibodies against all three rat IAP genes. Northern and Western blot analysis detected rat IAP transcripts and proteins in majority of the tissues examined. In addition, a shorter, alternatively spliced transcript corresponding to iap-2 was found in testes.
        
        
          Conclusions
          We have identified three rat homologues of the IAP genes. The elevated expression of rat iap-1 and iap2 in testes suggests that these two genes play an important antiapoptotic role in spermatogenesis.
Drug Abuse Warning Network (DAWN-2009)

<p>The Drug Abuse Warning Network (DAWN) is a nationally representative public health surveillance system that has monitored drug related emergency department (ED) visits to hospitals since the early 1970s. First administered by the Drug Enforcement Administration (DEA) and the National Institute on Drug Abuse (NIDA), the responsibility for DAWN now rests with the Substance Abuse and Mental Health Services Administration's (SAMHSA) Center for Behavioral Health Statistics and Quality (CBHSQ). Over the years, the exact survey methodology has been adjusted to improve the quality, reliability, and generalizability of the information produced by DAWN. The current approach was first fully implemented in the 2004 data collection year.<br />
DAWN relies on a longitudinal probability sample of hospitals located throughout the United States. To be eligible for selection into the DAWN sample, a hospital must be a non-Federal, short-stay, general surgical and medical hospital located in the United States, with at least one 24-hour ED. DAWN cases are identified by the systematic review of ED medical records in participating hospitals. The unit of analysis is any ED visit involving recent drug use. DAWN captures both ED visits that are directly caused by drugs and those in which drugs are a contributing factor but not the direct cause of the ED visit. The reason a patient used a drug is not part of the criteria for considering a visit to be drug-related. Therefore, all types of drug-related events are included: drug misuse or abuse, accidental drug ingestion, drug-related suicide attempts, malicious drug poisonings, and adverse reactions. DAWN does not report medications that are unrelated to the visit.<br />
The DAWN public-use dataset provides information for all types of drugs, including illegal drugs, prescription drugs, over-the-counter medications, dietary supplements, anesthetic gases, substances that have psychoactive effects when inhaled, alcohol when used in combination with other drugs (all ages), and alcohol alone (only for patients aged 20 or younger). Public-use dataset variables describe and categorize up to 22 drugs contributing to the ED visit, including toxicology confirmation and route of administration. Administrative variables specify the type of case, case disposition, categorized episode time of day, and quarter of year.  Metropolitan area is included for represented metropolitan areas. Created variables include the number of unique drugs reported and case-level indicators for alcohol, non-alcohol illicit substances, any pharmaceutical, non-medical use of pharmaceuticals, and all misuse and abuse of drugs. Demographic items include age category, sex, and race/ethnicity. Complex sample design and weighting variables are included to calculate various estimates of drug-related ED visits for the Nation as a whole, as well as for specific metropolitan areas, from the ED visits classified as DAWN cases in the selected hospitals.This study has 1 Data Set.</p>
Patent AT-E401713-T1: [Translated] METHOD FOR REALIZING A MULTICAST SERVICE

The present invention discloses a method for implementing multicast services, which includes: preset a mapping relation between a multicast user address and a multicast group address; acquire a request packet sent by the multicast user who requests to join in the multicast group; determine whether the multicast group address in request packet is the same as that corresponding to the multicast user in the established mapping relation according to the multicast user address and multicast group address carried in the request packet. If yes, allow the multicast user to join in the multicast group. Otherwise, reject the multicast user from joining in the multicast group. The present invention can open the preset multicast resources to the preset multicast user with speed and pertinence. At the same time, it limits the maximum number of multicast groups that each multicast user is allowed to join in, which can effectively control multicast service bandwidth and further protect the network equipment.
Compound 527839: 4,6-Diisopropyl-m-cresol

Chemical compound data from PubChem database. IUPAC Name: 5-methyl-2,4-di(propan-2-yl)phenol. Molecular Formula: C13H20O. Molecular Weight: 192.3. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Patent AT-E40142-T1: [Translated] LIQUID COATING COMPOSITION AND METHOD OF COATING SUBSTRATES USING THIS COATING COMPOSITION.

The invention provides a liquid coating composition curable at ambient temperature comprising an acetoacetate groups-containing addition polymer having a number average molecular weight of 1000-100 000, a glass transition temperature of 250°-370°K, a hydroxyl number of 0-200 and a content of acetoacetate groups of 3,5-45% by weight, the acetoacetate groups being present as ester of hydroxyalkyl acrylate, hydroxyalkyl methacrylate or allyl alcohol structural units, and a polyamine having primary and/or secondary amino groups and blocked with an aldehyde or ketone. A process for coating a substrate with such composition is also provided.
Phorbol ester impairs electrical excitation of rat pancreatic beta-cells through PKC-independent activation of K

Background
          Phorbol 12-myristate 13-acetate (PMA) is often used as an activating phorbol ester of protein kinase C (PKC) to investigate the roles of the kinase in cellular functions. Accumulating lines of evidence indicate that in addition to activating PKC, PMA also produces some regulatory effects in a PKC-independent manner. In this study, we investigated the non-PKC effects of PMA on electrical excitability of rat pancreatic β-cells by using patch-clamp techniques.
        
        
          Results
          In current-clamp recording, PMA (80 nM) reversibly inhibited 15 mM glucose-induced action potential spikes superimposed on a slow membrane depolarization and this inhibition can not be prevented by pre-treatment of the cell with a specific PKC inhibitor, bisindolylmaleimide (BIM, 1 μM). In the presence of a subthreshold concentration (5.5 mM) of glucose, PMA hyperpolarized β-cells in a concentration-dependent manner (0.8–240 nM), even in the presence of BIM. Based on cell-attached single channel recordings, PMA increased ATP-sensitive K+ channel (KATP) activity. Based on inside-out patch-clamp recordings, PMA had little effect on KATP activity if no ATP was in the bath, while PMA restored KATP activity that was suppressed by 10 μM ATP in the bath. In voltage-clamp recording, PMA enhanced tolbutamide-sensitive membrane currents elicited by repetitive ramp pulses from -90 to -50 mV in a concentration-dependent manner, and this potentiation could not be prevented by pre-treatment of cell with BIM. 4α-phorbol 12,13-didecanoate (4α-PDD), a non-PKC-activating phorbol ester, mimicked the effect of PMA on both current-clamp and voltage-clamp recording configurations. With either 5.5 or 16.6 mM glucose in the extracellular solution, PMA (80 nM) increased insulin secretion from rat islets. However, in islets pretreated with BIM (1 μM), PMA did not increase, but rather reduced insulin secretion.
        
        
          Conclusion
          In rat pancreatic β-cells, PMA modulates insulin secretion through a mixed mechanism: increases insulin secretion by activation of PKC, and meanwhile decrease insulin secretion by impairing β-cell excitability in a PKC-independent manner. The enhancement of KATP activity by reducing sensitivity of KATP to ATP seems to underlie the PMA-induced impairment of β-cells electrical excitation in response to glucose stimulation.